271 related articles for article (PubMed ID: 11208095)
1. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
Qi L; Ostrand-Rosenberg S
Traffic; 2000 Feb; 1(2):152-60. PubMed ID: 11208095
[TBL] [Abstract][Full Text] [Related]
2. Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system.
Oxenius A; Bachmann MF; Ashton-Rickardt PG; Tonegawa S; Zinkernagel RM; Hengartner H
Eur J Immunol; 1995 Dec; 25(12):3402-11. PubMed ID: 8566030
[TBL] [Abstract][Full Text] [Related]
3. Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules.
Pathak SS; Blum JS
Traffic; 2000 Jul; 1(7):561-9. PubMed ID: 11208144
[TBL] [Abstract][Full Text] [Related]
4. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.
Dissanayake SK; Tuera N; Ostrand-Rosenberg S
J Immunol; 2005 Feb; 174(4):1811-9. PubMed ID: 15699107
[TBL] [Abstract][Full Text] [Related]
5. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis.
Mukherjee P; Dani A; Bhatia S; Singh N; Rudensky AY; George A; Bal V; Mayor S; Rath S
J Immunol; 2001 Sep; 167(5):2632-41. PubMed ID: 11509605
[TBL] [Abstract][Full Text] [Related]
6. Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell.
Lombard-Platlet S; Bertolino P; Deng H; Gerlier D; Rabourdin-Combe C
Immunology; 1993 Dec; 80(4):566-73. PubMed ID: 7508420
[TBL] [Abstract][Full Text] [Related]
7. Class II MHC molecules can use the endogenous pathway of antigen presentation.
Nuchtern JG; Biddison WE; Klausner RD
Nature; 1990 Jan; 343(6253):74-6. PubMed ID: 1967486
[TBL] [Abstract][Full Text] [Related]
8. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
9. MHC class I presentation of an exogenous polypeptide antigen encoded by the murine AIDS defective virus.
Yee ST; Okada Y; Ogasawara K; Omura S; Takatsuki A; Kakiuchi T; Muno D; Kominami E; Mizuochi T
Microbiol Immunol; 1997; 41(7):563-70. PubMed ID: 9272702
[TBL] [Abstract][Full Text] [Related]
10. Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells.
Voeten JT; Rimmelzwaan GF; Nieuwkoop NJ; Fouchier RA; Osterhaus AD
Clin Exp Immunol; 2001 Sep; 125(3):423-31. PubMed ID: 11531950
[TBL] [Abstract][Full Text] [Related]
11. Selective increased presentation of type II collagen by leupeptin.
Manoury-Schwartz B; Chiocchia G; Lotteau V; Fournier C
Int Immunol; 1997 Apr; 9(4):581-9. PubMed ID: 9138019
[TBL] [Abstract][Full Text] [Related]
12. MHC class II-restricted presentation of native protein antigen by B cells is inhibitable by cycloheximide and brefeldin A.
St-Pierre Y; Watts TH
J Immunol; 1990 Aug; 145(3):812-8. PubMed ID: 2373860
[TBL] [Abstract][Full Text] [Related]
13. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.
Qi L; Rojas JM; Ostrand-Rosenberg S
J Immunol; 2000 Nov; 165(10):5451-61. PubMed ID: 11067897
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.
Robson NC; Donachie AM; Mowat AM
Eur J Immunol; 2008 May; 38(5):1238-46. PubMed ID: 18398931
[TBL] [Abstract][Full Text] [Related]
15. Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells.
Adorini L; Ullrich SJ; Appella E; Fuchs S
Nature; 1990 Jul; 346(6279):63-6. PubMed ID: 2366863
[TBL] [Abstract][Full Text] [Related]
16. Alternative processing for MHC class I presentation by immature and CpG-activated dendritic cells.
Chen L; Jondal M
Eur J Immunol; 2004 Apr; 34(4):952-60. PubMed ID: 15048705
[TBL] [Abstract][Full Text] [Related]
17. Influenza A virus infection-induced macroautophagy facilitates MHC class II-restricted endogenous presentation of an immunodominant viral epitope.
Deng J; Lu C; Liu C; Oveissi S; Fairlie WD; Lee EF; Bilsel P; Puthalakath H; Chen W
FEBS J; 2021 May; 288(10):3164-3185. PubMed ID: 33830641
[TBL] [Abstract][Full Text] [Related]
18. Cytosolic targeting of hen egg lysozyme gives rise to a short-lived protein presented by class I but not class II major histocompatibility complex molecules.
Calin-Laurens V; Forquet F; Mottez E; Kanellopoulos J; Godeau F; Kourilsky P; Gerlier D; Rabourdin-Combe C
Eur J Immunol; 1991 Mar; 21(3):761-9. PubMed ID: 2009914
[TBL] [Abstract][Full Text] [Related]
19. Processing of endogenously synthesized hen egg-white lysozyme retained in the endoplasmic reticulum or in secretory form gives rise to a similar but not identical set of epitopes recognized by class II-restricted T cells.
Adorini L; Guéry JC; Fuchs S; Ortiz-Navarrete V; Hämmerling GJ; Momburg F
J Immunol; 1993 Oct; 151(7):3576-86. PubMed ID: 7690807
[TBL] [Abstract][Full Text] [Related]
20. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells.
Brooks AG; McCluskey J
J Immunol; 1993 May; 150(9):3690-7. PubMed ID: 8473726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
